Clinical samples are rarely perfect. FFPE material is a standard collection but degraded RNA, limited tissue, and complex downstream questions can make bulk gene expression analysis difficult to plan and even harder to interpret.
In this webinar, Propath explores practical strategies for gene expression analysis in challenging clinical samples, with a focus on how to compare, validate, and integrate different technologies in translational research.
1. Compare the right platforms for the right question
RNA-seq, qPCR, nCounter, and spatial workflows each answer different questions. We will discuss where each technology fits, where it struggles, and how to choose the right approach for FFPE-based clinical development.
2. Understand GxP validation considerations
Learn what matters when moving from preclinical biomarker research toward regulated workflows that need stronger validation, traceability, and reproducibility.
3. Connect data analysis with pathology context
Gene expression data becomes more useful when it is interpreted alongside tissue quality and histopathological observations.
4. Place bulk expression within an integrated multiomics strategy
Bulk gene expression analysis in FFPE tissue such as nCounter can support a broader translational plan, bridging discovery, targeted signature validation, and spatial biology.
5. Explore a clinical case study
See how downstream multimodal analysis can help connect molecular readouts, tissue context, and clinical development decisions, with real examples from Biopharma.
Who should attend?
This webinar is for translational scientists, biomarker leads, clinical development teams, biotech executives, and pharma decision-makers working with FFPE samples, gene expression data, or biomarker validation etc.
Why attend?
Because “the RNA is degraded” should not be the end of the conversation. Join this Propath webinar to learn how to make informed technology choices, reduce biomarker uncertainty, and extract meaningful gene expression insights from difficult clinical material.
Kelly Hunter is Chief Scientific Officer at Propath UK, where he leads the company’s scientific strategy and development of advanced spatial biology services across spatial proteomics, spatial transcriptomics, multiplex immunofluorescence and single-cell spatial analysis. With substantial experience in implementing and commercialising cutting-edge tissue profiling technologies, Kelly works closely with pharmaceutical and biotechnology partners to design translational research and biomarker strategies that generate meaningful, decision-ready data from limited clinical samples. His expertise spans complex assay development, custom high-plex panel design, spatial multiomics workflows and the integration of robust bioinformatics to translate rich tissue data into actionable biological insight. At Propath, Kelly helps clients apply responsive, GCP-compliant spatial biology solutions to support mechanism-of-action studies, biomarker discovery, clinical trial delivery and confident decision-making across the drug development pipeline.
Dave Swatman leads Propath’s commercial operations and strategic partnerships. He has extensive experience supporting pharmaceutical and biotechnology companies through outsourced pathology and translational research services and has played a key role in the commercial launch of Propath’s spatial biology capabilities.
